Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity

Journal of Thoracic and Cardiovascular Surgery

Volumn 139, Issue 6, 2010, Pages 1587-1593

  Blasberg, Justin D ^a   Goparaju, Chandra M ^a   Pass, Harvey I ^a   Donington, Jessica S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BRONCHUS MUCOSA; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PROTEIN ISOFORMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952321457     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.08.016     Document Type: Article

References (25)

1. Donati V., Boldrini L., Dell'Omodarme M., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11 (2005) 6459-6465
2. Hu Z., Lin D., Yuan J., et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11 (2005) 4646-4652
3. Lucchi M., Fontanini G., Mussi A., et al. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 12 (1997) 535-541
4. Duarte I.G., Bufkin B.L., Pennington M.F., et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 115 (1998) 652-659
5. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., and Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340 (1992) 145-146
6. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
7. Shibusa T., Shijubo N., and Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4 (1998) 1483-1487
8. Takanami I., Tanaka F., Hashizume T., and Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res 17 (1997) 2811-2814
9. Fontanini G., Vignati S., Bigini D., et al. Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development. Int J Cancer 67 (1996) 615-619
10. Shijubo N., Uede T., Kon S., Nagata M., and Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11 (2000) 135-146
11. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., and Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149 (1996) 293-305
12. Shijubo N., Uede T., Kon S., et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160 (1999) 1269-1273
13. Kang I.C., Lee Y.D., and Kim D.S. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res 59 (1999) 3754-3760
14. Vasile E., Qu H., Dvorak H.F., and Dvorak A.M. Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J Histochem Cytochem 47 (1999) 159-167
15. Senger D.R., Wirth D.F., and Hynes R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16 (1979) 885-893
16. Ashkar S., Weber G.F., Panoutsakopoulou V., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287 (2000) 860-864
17. Liaw L., Birk D.E., Ballas C.B., Whitsitt J.S., Davidson J.M., and Hogan B.L. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101 (1998) 1468-1478
18. Denhardt D.T., and Guo X. Osteopontin: a protein with diverse functions. FASEB J 7 (1993) 1475-1482
19. Behrend E.I., Craig A.M., Wilson S.M., Denhardt D.T., and Chambers A.F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54 (1994) 832-837
20. Gardner H.A., Berse B., and Senger D.R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9 (1994) 2321-2326
21. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
22. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
23. Brooks P.C., Montgomery A.M., Rosenfeld M., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
24. Max R., Gerritsen R.R., Nooijen P.T., et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71 (1997) 320-324
25. Goto F., Goto K., Weindel K., and Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 69 (1993) 508-517